GW9662 ameliorates nonalcoholic steatohepatitis by inhibiting the PPARγ/CD36 pathway and altering the gut microbiota.

Jing Xiao,Huanyu Xiang,Hongyan Xiang, Zilin Sun,Jing Xu,Hong Ren,Peng Hu,Mingli Peng

European journal of pharmacology（2023）

引用 0|浏览9

暂无评分

摘要

GW9662 ameliorated lipid metabolism by inhibiting the PPARγ/CD36 pathway and altering the composition of the gut microbiota in NASH mice. Therefore, the PPARγ antagonist GW9662 deserves more attention as a potential therapeutic agent for NASH.

查看译文

关键词

nonalcoholic steatohepatitis,gut microbiota,pathway,pparγ/cd36

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要